Dendreon (DNDN -4.4%) shares slump after Robert W. Baird cuts its price target to $14 from $20...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN -4.4%) shares slump after Robert W. Baird cuts its price target to $14 from $20 and lowers its sales forecast for its Provenge prostate cancer drug. Oncologists say they haven't been reimbursed yet for the drug because of Medicare and regional carrier issues, according to Baird's research note.